IP Library Granted Patent US 8,367,080
Granted Patent B2
US 8,367,080 · App. 13/157,579 · Granted Feb 5, 2013

Pharmaceutical formulation for use in HIV therapy

Inventors: Kiran Kumar Narsaiah Velaveni (Secunderabad, IN); Sanjay Deshraj Verma (Secunderabad, IN); Akhilesh Ashok Dixit (Secunderabad, IN); Abhijit Mukund Deshmukh (Secunderabad, IN); Sanjeev Meharchand Sethi (Secunderabad, IN)
Assignee: Mylan Laboratories Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,367,080
App. No.
13/157,579
Granted
Feb 5, 2013
Kind
B2
Abstract

The invention discloses a formulation prepared by granulating at least one anti-retro viral drug and at least one pharmaceutically acceptable additive, using an organic solvent; milling the product; finally processing the milled product to form tablets or capsules.

Claims (12)

1. A process of preparing a pharmaceutical formulation, comprising the steps of:

a. preparing a paste comprising ritonavir, copovidone, colloidal silicon dioxide and a solubilizing agent, using dichloromethane;

b. removing dichloromethane from said paste under vacuum and milling the paste to form granules;

c. lubricating said granules with a lubricant;

d. compressing said lubricated granules into tablets or filling it into capsules.

2. The process according to claim 1 , wherein the lubricant is sodium stearyl fumarate.

3. The process according to claim 1 , wherein the paste components of step (a) further comprises lopinavir.

4. The process according to claim 1 , wherein the solubilizing agent is sorbitan laurate.

5. The process according to claim 1 , wherein the solubilizing agent is glycerol monooleate.

6. The process according to claim 1 , wherein the paste further comprises poloxamer or hydroxypropylmethyl cellulose.

7. The process according to claim 1 , wherein the paste is prepared by mixing ritinovir, sorbitan oleate, copovidone and colloidal silicon dioxide, and subsequently granulating said mixture with dichloromethane.

8. The process of claim 1 , wherein the paste is prepared by dissolving ritonavir and sorbitan laureate in dichloromethane and granulating said solution with copovidone and colloidal silicon dioxide.

Assignments (2)
CHANGE OF NAME Recorded Feb 9, 2012
From: MATRIX LABORATORIES LIMITED
To: MYLAN LABORATORIES LIMITED
Reel/Frame 027678/0674 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2011
From: VELAVENI, KIRAN KUMAR NARSAIAH; VERMA, SANJAY DESHRAJ; DIXIT, AKHILESH ASHOK; DESHMUKH, ABHIJIT MUKUND; SETHI, SANJEEV MEHARCHAND; MITRA, SOURAV DILIPKUMAR
To: MATRIX LABORATORIES LIMITED
Reel/Frame 026440/0831 →
Priority Claims (1)
IN 1597/CHE/2006 · Sep 4, 2006 · national
Continuity (2)
Continuation 12310693
Related Publication 20110262533A1 · Oct 27, 2011